scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1103148499 |
P356 | DOI | 10.1186/S13098-018-0327-4 |
P932 | PMC publication ID | 5883417 |
P698 | PubMed publication ID | 29636825 |
P2093 | author name string | Rodrigo Oliveira Moreira | |
Roberta Cobas | |||
Raquel C Lopes Assis Coelho | |||
P2860 | cites work | Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial | Q50233425 |
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial. | Q51246488 | ||
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. | Q51278923 | ||
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. | Q51280414 | ||
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). | Q51317501 | ||
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with typ | Q53261592 | ||
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes | Q26784381 | ||
A systematic review of the associations between dose regimens and medication compliance | Q30719289 | ||
Interventions for helping patients to follow prescriptions for medications | Q30868125 | ||
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. | Q33834266 | ||
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes | Q36050559 | ||
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy | Q36360100 | ||
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial | Q36554610 | ||
IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test | Q36638917 | ||
Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people | Q37278100 | ||
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes | Q37337304 | ||
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial | Q37639300 | ||
Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review | Q38074481 | ||
Long-term effectiveness and safety of liraglutide in clinical practice. | Q38084102 | ||
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial | Q38395267 | ||
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes | Q38400563 | ||
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance | Q38542098 | ||
Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving? | Q38626133 | ||
The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes | Q38629197 | ||
An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review | Q38664374 | ||
Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges | Q39015857 | ||
Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes | Q39408293 | ||
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes | Q40105411 | ||
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 | ||
Basal insulin and cardiovascular and other outcomes in dysglycemia | Q42507791 | ||
Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem | Q46611567 | ||
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. | Q47556600 | ||
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. | Q49988613 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | type 2 diabetes | Q3025883 |
P304 | page(s) | 26 | |
P577 | publication date | 2018-04-03 | |
P1433 | published in | Diabetology and Metabolic Syndrome | Q15816649 |
P1476 | title | Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? | |
P478 | volume | 10 |
Q92128367 | BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion |
Q92135193 | Clinical and psychological characteristics of liraglutide treatment among patients with type 2 diabetes |
Q92270000 | Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force |
Q92262738 | Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial |
Q92442104 | IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy |
Q89949315 | Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study |
Q90409273 | The Evolving Treatment of Diabetic Retinopathy |
Search more.